Research

The Zheng Research Group pioneers the development of innovative radiopharmaceuticals to transform the diagnosis and treatment of neuropsychiatric and neurodegenerative disorders. By harnessing the latest advancements in organic chemistry, radiochemistry, and pharmacology, our team designs groundbreaking imaging agents that reveal the intricate biochemical changes in the brain associated with neurological conditions. These cutting-edge tools enable clinicians and researchers to visualize disease progression and therapeutic responses with unprecedented clarity. 

Unlocking the secrets of the brain requires tools as sophisticated as the challenges themselves. The Zheng Research Group specializes in designing and developing PET radioligands that revolutionize imaging for various neurological and psychiatric disorders. By integrating medicinal chemistry, radiochemistry, and quantitative PET imaging, our lab develops radioligands capable of capturing biochemical and phenotypic changes in vivo. From preclinical models to clinical applications, these radioligands provide critical insights into disease mechanisms and treatment efficacy.

At the core of the Zheng Research Group’s work is the development of cutting-edge methodologies for Carbon-11 and Fluorine-18 labeling, the foundational isotopes for PET imaging. By adapting advanced organic chemistry reactions for radiochemical applications, we create versatile tools for probing the molecular underpinnings of neuropsychiatric and neurodegenerative diseases. Our team’s work not only advances the science of radiolabeling but also enables precise imaging of brain functions and disorders in both preclinical and clinical settings.